Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections. - Wikidata - awgldk - TriplyDB

Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections.

Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections.

http://www.wikidata.org/entity/Q34955858

about

Advances in MRSA drug discovery: where are we and where do we need to be?Utility of the Biosynthetic Folate Pathway for Targets in Antimicrobial Discovery.Synthesis, antifungal activity, and QSAR studies of 1,6-dihydropyrimidine derivatives.Synthesis, anti-angiogenic and DNA cleavage studies of novel N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)piperidine-4-carboxamide derivatives.An Updated Review of Iclaprim: A Potent and Rapidly Bactericidal Antibiotic for the Treatment of Skin and Skin Structure Infections and Nosocomial Pneumonia Caused by Gram-Positive Including Multidrug-Resistant Bacteria.

P2860

Q37112508-0C3A08C6-ECAA-4EEC-933E-F3520CE96122 Q38792855-8C141F80-0557-4058-80D9-129FA93B0FFB Q42881862-FE9A669D-70E2-4A7C-B4F1-6E2E40AA0F00 Q47154777-1D45D076-C269-4DDE-A6D7-EA89D23D4CC1 Q49310486-5C989DA7-E973-49DF-9C70-28895CDADF24

P2860

Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections.

http://www.wikidata.org/entity/Q34955858

description

2009 nî lūn-bûn

@nan

2009 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մարտին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections.

@ast

Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections.

@en

Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections.

@nl

type

label

Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections.

@ast

Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections.

@en

Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections.

@nl

prefLabel

Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections.

@ast

Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections.

@en

Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections.

@nl

P1433

Q34955858-81A48983-D394-4FA8-9EA5-9F97C1C7389B

P1476

Q34955858-D257EA3E-BE8E-41BD-AAFD-F8AAE429521B

P2093

Q34955858-60FEA134-99FF-4CF7-A297-CD690CDAADF9

Q34955858-6F3E6252-D753-410B-BD3E-04882A062FDF

Q34955858-C3788605-C27A-4BC8-9E87-3E044B2EEB48

P2860

Q34955858-256E8565-FECF-48F6-A388-5AD17FC73819

Q34955858-315C97EB-710D-4121-8EBF-534E1B7297C9

Q34955858-354CC898-415B-4A2B-B4EC-AEDB7CBE4336

Q34955858-3E7945C0-22F0-4045-B663-4326241FA80A

Q34955858-46C27140-B8D5-432D-BEBE-E74C15D31ECB

Q34955858-808784AD-7407-43E6-B057-E40E4FBABDC9

Q34955858-839FF035-9FAE-45FD-AD0A-83D0DC3E5E8C

Q34955858-84E25BAF-D4F9-45D8-9A88-5679A9199F83

Q34955858-9806D271-35BE-4801-920C-D42D0BAF6AA1

Q34955858-A1A91588-D77B-455D-8363-6EF9CD8E63AC

P304

Q34955858-45A4B57B-FAAE-4CA6-AEF7-01284CA018D0

P31

Q34955858-3A12F54F-A04D-4E3B-A278-AC095AA94165

P356

Q34955858-00CC7EAD-E8CD-4FFE-B027-CDCFA0AED473

P433

Q34955858-A6A108A2-CEF0-41C1-96EB-C81F48353C74

P478

Q34955858-AE2DF861-F4E2-4628-BC35-4FB102B1ABBA

P577

Q34955858-D6FA68EF-F5F7-464A-911B-67786D4F52B4

P698

Q34955858-B2E16B14-CFD3-4BCF-B4C1-D643BD77FB16

P356

17460913.4.2.131

P1433

Future Microbiology

P1476

Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections.

@en

P2093

Andrew Morgan

http://www.w3.org/2001/XMLSchema#string

Christine Cofer

http://www.w3.org/2001/XMLSchema#string

Dennis L Stevens

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

Registered and Investigational Drugs for the Treatment of Methicillin-Resistant Staphylococcus aureus Infection

Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria.

Practice guidelines for the diagnosis and management of skin and soft-tissue infections.

Gram-positive resistance: pathogens, implications, and treatment options: insights from the Society of Infectious Diseases Pharmacists.

The management of infections due to drug-resistant gram-positive bacteria.

Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy.

Combating the growing problem of methicillin-resistant Staphylococcus aureus: do the newer antibiotics represent a better alternative to vancomycin?

Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.

Concentrations in plasma, epithelial lining fluid, alveolar macrophages and bronchial mucosa after a single intravenous dose of 1.6 mg/kg of iclaprim (AR-100) in healthy men.

P304

131-144

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/17460913.4.2.131

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2009-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19257839

http://www.w3.org/2001/XMLSchema#string